Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

医学 内科学 打开标签 肿瘤科 临床试验
作者
Milind Javle,Sameek Roychowdhury,Robin Kate Kelley,Saeed Sadeghi,Teresa Macarulla,Karl Heinz Weiss,Dirk‐Thomas Waldschmidt,Lipika Goyal,Ivan Borbath,Anthony B. El-Khoueiry,Mitesh J. Borad,Wei Peng Yong,Philip A. Philip,Michael Bitzer,S. Tanasanvimon,Li Ai,Amit Pande,Harris S. Soifer,Stacie Peacock Shepherd,Susan Moran
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:6 (10): 803-815 被引量:419
标识
DOI:10.1016/s2468-1253(21)00196-5
摘要

Background Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements occur in 10–16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2 alterations, and previous gemcitabine-based treatment. Methods This multicentre, open-label, single-arm, phase 2 study recruited patients from 18 academic centres and hospitals in the USA, Belgium, Spain, Germany, Singapore, Taiwan, and Thailand. Eligible participants were aged 18 years or older, had histologically or cytologically confirmed, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, and were previously treated with at least one gemcitabine-containing regimen. Patients received 125 mg of oral infigratinib once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death. Radiological tumour evaluation was done at baseline and every 8 weeks until disease progression via CT or MRI of the chest, abdomen, and pelvis. The primary endpoint was objective response rate, defined as the proportion of patients with a best overall response of a confirmed complete or partial response, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors, version 1.1. The primary outcome and safety were analysed in the full analysis set, which comprised all patients who received at least one dose of infigratinib. This trial is registered with ClinicalTrials.gov, NCT02150967, and is ongoing. Findings Between June 23, 2014, and March 31, 2020, 122 patients were enrolled into our study, of whom 108 with FGFR2 fusions or rearrangements received at least one dose of infigratinib and comprised the full analysis set. After a median follow-up of 10·6 months (IQR 6·2–15·6), the BICR-assessed objective response rate was 23·1% (95% CI 15·6–32·2; 25 of 108 patients), with one confirmed complete response in a patient who only had non-target lesions identified at baseline and 24 partial responses. The most common treatment-emergent adverse events of any grade were hyperphosphataemia (n=83), stomatitis (n=59), fatigue (n=43), and alopecia (n=41). The most common ocular toxicity was dry eyes (n=37). Central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) patients, of which ten (9%) were grade 1, seven (6%) were grade 2, and one (1%) was grade 3. There were no treatment-related deaths. Interpretation Infigratinib has promising clinical activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements, and so represents a potential new therapeutic option in this setting. Funding QED Therapeutics and Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
奈何完成签到 ,获得积分10
1秒前
不吃辣完成签到,获得积分10
2秒前
3秒前
3秒前
爱岗敬业牛马人完成签到,获得积分10
3秒前
林慧宁发布了新的文献求助10
3秒前
zzz完成签到,获得积分10
4秒前
5秒前
Menand发布了新的文献求助10
7秒前
隐形曼青的应助被花样年华采纳,获得10
7秒前
xhjiang完成签到,获得积分10
7秒前
刺五加发布了新的文献求助10
8秒前
CaliU发布了新的文献求助10
10秒前
10秒前
努力发AM完成签到,获得积分10
11秒前
清心发布了新的文献求助10
13秒前
14秒前
14秒前
14秒前
乌龙茶完成签到 ,获得积分10
14秒前
14秒前
CJX发布了新的文献求助10
15秒前
车辆学长完成签到 ,获得积分10
15秒前
花样年华发布了新的文献求助10
19秒前
盟主完成签到 ,获得积分10
20秒前
沉静蓉发布了新的文献求助10
20秒前
超表面发布了新的文献求助10
20秒前
annie完成签到 ,获得积分10
22秒前
碧蓝老黑完成签到,获得积分10
22秒前
李健的应助被wm采纳,获得10
22秒前
24秒前
24秒前
24秒前
25秒前
思念变成王年年完成签到,获得积分10
25秒前
27秒前
坚强孤容发布了新的文献求助10
28秒前
LpmxRk发布了新的文献求助10
28秒前
任性子骞完成签到,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712